Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.

Catalysis SL15 enrolled

Overview

Oral mucositis is one of the most spread side effects of anticancer therapy. It is associated with both chemo- and radiotherapy, decreases QoL, relative dose intensity and leads to nutritive deficiency. Oral mucositis causes secondary infections, increased hospital stay, whereas pain syndrome results in an emotional distress, anorexia and disables natural feeding.

Primary: To evaluate the efficacy of ONCOXIN on oral mucositis symptoms in patients who receive chemotherapy and/or radiotherapy. Secondary: To evaluate the effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Mucositis Oral

Interventions

Oncoxin®DIETARY_SUPPLEMENT

Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;

Eligibility

Sex: ALLMin age: 45 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. A signed and dated informed consent form; 2. Patients of both genders, aged 45-75; 3. Malignant neoplasms which have radio-, chemotherapy or their combinations prescribed; 4. ECOG ≤3; 5. WHO oral toxicity scale grade 2 - 3. Exclusion Criteria: 1. Significant, according to the investigator judgement, concomitant diseases or states which make it complicate or even impossible the patient's participation in the study or make it difficult to interpret the clinical data obtained in any stage of the study always including the following: * Mental disorders; * Serious/chronic infectious and parasitic diseases; * Intolerability to any of ONCOXIN components. 2. Relations with study center personnel (study center staff or family member of the investigator, coordinator or assistant). 3. If the patient fails to assess his/her physical and emotional condition; 4. If the patient fails to comply with the requirements; 5. Patient's refusal to participate in the study; 6. Pregnancy or lactation.

Locations (1)

Medical Scientific centre of professor Shumsky

Samara, Samara Oblast, Russia

Outcomes

Primary Outcomes

Oral mucositis grade in patients during chemotherapy and radiotherapy treatments

Efficacy of OCOXIN on oral mucositis symptoms in patients who receive chemotherapy and/or radiotherapy with WHO oral toxicity scale grades. The WHO scale is dependent on both objective and subjective variables, and measures anatomical, symptomatic as well as functional components of oral mucositis. WHO Oral Mucositis Grading Scale: * 0 (none): None * I (mild): Oral soreness, erythema * II (moderate): Oral erythema, ulcers, solid diet tolerated * III (severe): Oral ulcers, liquid diet only * IV (life-threatening): Oral alimentation impossible

Time frame: 21 days

Secondary Outcomes

Nutritional status of the patients during Chemotherapy and radiotherapy treatments related with weight gain

Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with body mass measures.

Time frame: 21 days

Nutritional status of the patients during Chemotherapy and radiotherapy treatments

Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with days with the intake of regular food.

Time frame: 21 days

Nutritional status of the patients during Chemotherapy and radiotherapy treatments

Effects of ONCOXIN on nutritional status in patients who receive chemotherapy and/or radiotherapy measured with days with no loss of appetite complaints.

Time frame: 21 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.